Brand Reference: Paxil, Brisdelle (7.5 mg vasomotor)
| Metric | Verified Benchmark | Source |
|---|---|---|
| Paroxetine Hydrochloride RxNorm Concept ID | 32937 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0520 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $36.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $5.50 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $7.00 / mo | 27 Zero-PHI Verified Patient Logs |
Highest biochemical SERT binding affinity (Ki ~0.13 nM) in the SSRI class; approved both at 20–40 mg for severe social/panic anxiety and at ultra-low 7.5 mg (Brisdelle) as a non-hormonal hypothalamic thermoregulatory treatment for menopausal vasomotor hot flashes.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Paroxetine Hydrochloride (Paxil / Brisdelle (7.5 mg vasomotor), RxCUI 32937) at $0.0520 per unit, whereas walk-in chain pharmacies bill cash patients an average of $36.00 monthly—creating a 85% ($30.50/mo) wholesale arbitrage spread down to $5.50.
Systemic exposure to Paroxetine Hydrochloride reflects 64% oral after saturable first-pass absorption kinetics and potent cyp2d6 mechanism-based inhibitor (never combine with tamoxifen—blocks endoxifen activation!), sustaining receptor engagement across a 21 hours (non-linear autoinhibition of CYP2D6) half-life window (2 weeks vasomotor hot-flash drop; 3–4 weeks panic control response profile).
Dosing protocols (7.5 mg PO QHS (non-hormonal vasomotor hot flashes) or 10–20 mg PO daily or 40 mg PO daily) balance efficacy (76.40% patient satisfaction across 27 logs) against discontinuation dizziness without slow taper (33% of reports), weight gain (28% of reports), anticholinergic dry mouth (19% of reports), with strict avoidance in tamoxifen co-administration (abolishes cyp2d6 endoxifen breast-cancer protection); maoi within 14 days; first-trimester pregnancy (cardiac septal risk).
Across 27 verified cash-pay logs, Paroxetine Hydrochloride achieves a 76.40% Worth-It rating with out-of-pocket spend averaging $7.00/mo versus $36.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 7.5 mg PO QHS (non-hormonal vasomotor hot flashes) for Paroxetine Hydrochloride; monthly out-of-pocket dropped to $4.84 compared with $36.00 retail.
Completed 10 weeks on Paroxetine Hydrochloride (10–20 mg PO daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 40 mg PO daily Paroxetine Hydrochloride sourced via TeleMed ($6.38/mo cash pay without insurance prior authorization).